Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal o...(x biologics and therapeutichypothermia d...)

Date:2/3/2009

x biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

       Copyright 2009 Cardium Therapeutics, Inc.  All rights reserved.
   For Terms of Use Privacy Policy, please visithttp://www.cardiumthx.com.
      Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
                              Therapeutics, Inc.
  Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM)
                   are trademarks of Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), Celsius Control System(R), RapidBlue(TM), CoolBlue(TM). Accutrol(R), Temperature Control Element(R) and

      TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc.
             (other trademarks belong to their respective owners)

'/>"/>

SOURCE Cardium Therapeutics Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK